AMR Stock Recent News

AMR LATEST HEADLINES

AMR Stock News Image - seekingalpha.com

Warrior Met Coal is slightly more attractive than Alpha Metallurgical Resources due to higher gross margins and average coal quality, but both remain fundamentally sound. Until metallurgical coal prices bottom and trade policy uncertainties dissipate, a Hold rating for both HCC and AMR seems justified. While valuations for both companies are historically high, HCC is currently relatively cheaper than AMR.

seekingalpha.com 2025 Jul 11
AMR Stock News Image - prnewswire.com

BRISTOL, Tenn. , July 8, 2025 /PRNewswire/ -- Alpha Metallurgical Resources, Inc. (NYSE: AMR), a leading U.S. supplier of metallurgical products for the steel industry, plans to announce its second quarter 2025 financial results before the market opens on Friday, August 8, 2025.

prnewswire.com 2025 Jul 08
AMR Stock News Image - seekingalpha.com

AMR is a well-managed, financially sound pure-play metallurgical coal producer with strong reserves and operational flexibility. Despite long-term demand prospects, the current metallurgical coal market faces oversupply, weak pricing, and uncertain recovery, pressuring AMR's margins and profitability. AMR has paused dividends and is likely to further scale back share buybacks to preserve cash amid challenging market conditions.

seekingalpha.com 2025 May 27
AMR Stock News Image - seekingalpha.com

Alpha Metallurgical Resources, Inc. (NYSE:AMR ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Emily O'Quinn - SVP-IR and Communications Andy Eidson - CEO Jason Whitehead - President and COO Todd Munsey - CFO Dan Horn - Chief Commercial Officer Conference Call Participants Nick Giles - B. Riley Securities Nathan Martin - The Benchmark Company Operator Greetings, and welcome to the Alpha Metallurgical Resources First Quarter 2025 Results Conference Call.

seekingalpha.com 2025 May 09
AMR Stock News Image - zacks.com

Alpha Metallurgical (AMR) came out with a quarterly loss of $2.60 per share versus the Zacks Consensus Estimate of a loss of $1.53. This compares to earnings of $9.59 per share a year ago.

zacks.com 2025 May 09
AMR Stock News Image - prnewswire.com

Reports first quarter net loss of $33.9 million Posts Adjusted EBITDA of $5.7 million for the quarter Increases size of ABL from $155 million to $225 million through amended and extended agreement with new expiration of May 2029 Reduces metallurgical coal sales volume guidance range to 13.8 million to 14.8 million tons for the year; adjusts down range of thermal coal shipment expectations to 0.8 million to 1.2 million tons Lowers 2025 capex guidance range to $130 million to $150 million BRISTOL, Tenn., May 9, 2025 /PRNewswire/ -- Alpha Metallurgical Resources, Inc. (NYSE: AMR), a leading U.S. supplier of metallurgical products for the steel industry, today reported financial results for the first quarter ending March 31, 2025.

prnewswire.com 2025 May 09
AMR Stock News Image - zacks.com

Alpha Metallurgical (AMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com 2025 May 02
AMR Stock News Image - businesswire.com

BOWLING GREEN, Ky.--(BUSINESS WIRE)--Holley Performance Brands (NYSE: HLLY), a leader in automotive aftermarket performance solutions, today announced a strategic collaboration with IndyCar for the 2025 race season. The company will outfit all 30 members of the AMR INDYCAR Safety Team—including physicians, paramedics, firefighters, EMTs and nurses—with top-rated Simpson fire suits to ensure the highest standards of protection. As part of this initiative, there will also be safety training throu.

businesswire.com 2025 Apr 03
AMR Stock News Image - zacks.com

AMR, APPF and EGBN have been added to the Zacks Rank #5 (Strong Sell) List on April 1, 2025.

zacks.com 2025 Apr 01
AMR Stock News Image - globenewswire.com

CAMBRIDGE, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR). TRANSCEND is designed to enroll approximately 120 kidney transplant recipients with late AMR.

globenewswire.com 2025 Mar 11
10 of 50